Business Wire

GSMA Partnership Programme Expands to Create the Largest IoT Community in Asia Pacific

Share

The GSMA APAC IoT Partnership Programme has expanded to include more than thirty mobile operators making it the largest IoT community in the Asia Pacific region (APAC), the GSMA announced today. The programme brings operators and their partners together including developers, manufacturers and system integrators to share best practice, discuss challenges and progress updates on the development of IoT across the region. The initiative has seen 7 operators open 9 new IoT Labs in the region to help develop new IoT-based solutions. APAC has the largest IoT market in the world and is expected to reach 11 billion connections by 2025 and be worth $386 billion, according to GSMA Intelligence.

“The programme has doubled in size in less than a year and that is testament to the support, engagement and commitment of the mobile operator community who are collaborating closely with their partners to lead the expansion and growth of IoT across the region,” said Julian Gorman, Head of Asia Pacific, GSMA. “This is now the largest cross-regional IoT community in the world and we are already seeing the impact it is having in terms of the development of new solutions. I look forward to seeing how it continues to grow in the coming years.”

APAC Impact

Since launch in October 2018, the APAC IoT Partnership Programme has had an instant impact throughout the region, encouraging more than 120 companies such as IoT developers or solutions companies to work with operators. The programme has also supported the development, design and funding of 9 new IoT Labs throughout the region that is encouraging the development of new products. The IoT labs are a key mechanism for collaboration, encouraging the joint development of new use cases, services and applications that are enabling IoT innovations to be effectively deployed. The programme has also held a series of workshops exploring key industry topics such as Mobile IoT, AI and 5G as well as offered capacity building for local regulators and stakeholders and provided best practice support.

Mobile IoT Experiencing Fastest Global Growth

The APAC region is the fastest growing IoT market in the world, accounting for approximately 40 per cent of the total global IoT spend in 2018. Global Low Power Wide Area (LPWA) or Mobile IoT network connections have also been driven primarily by the APAC region accounting for nearly 97% of all NB-IoT connections according to ABI Research. Mobile IoT networks are being merged into 5G standards to support low latency, massive IoT and large bandwidth. Thirty-seven of the world’s 119 Mobile IoT networks are also deployed in Asia Pacific across 15 countries. China in particular has been a key market in driving early adoption, accounting for 40 per cent of the global LPWA connections in 2018.

IoT @ GSMA Mobile 360 – Digital Societies

The GSMA IoT programme will host a number of different activities at GSMA M360 – Digital Societies held in Kuala Lumpur on Thursday 26 September 2019. This includes the APAC IoT Innovation Summit which provides attendees with insight from mobile operators and their partners on the latest developments in Mobile IoT. There will also be a number of interactive demos showcasing Mobile IoT, 5G, AI, Big Data Analytics, Blockchain and Drones at IoT Expo – Connected APAC. This will include hands on demonstrations from key industry verticals such as agriculture, aviation and retail and host smart home, smart traffic and smart poultry solutions. For further information, please go here: https://www.gsma.com/iot/events/m360-apac-iot-summit/#expo

The Birth of Beyond Connectivity

The GSMA will launch the ‘Beyond Connectivity’ campaign at Mobile 360 – Digital Societies. Beyond Connectivity describes how mobile operators are delivering innovation and transformative solutions to customers across big data, machine learning, analytics, edge computing and distributed ledger technologies and delivering beyond just data connectivity. To find out more, please go to: www.gsma.com/BeyondConnectivity

-ENDS-

Notes to Editors

  1. Operators include Axiata Group (Axiata Robi, Celcom, Dialog Axiata, Ncell, Smart Axiata, XL Axiata and Xpand), Indosat Ooredoo, Jazz, M1, Maxis, Mobitel, Smartfren, Singtel Group (Singtel, Optus), StarHub, Telenor Group (Digi, DTAC, Grameenphone, Telenor Connexion, Telenor Myanmar, Telenor Pakistan), Telstra, TM ONE, True, Rakuten, Viettel Group (Metfone, Mytel, Unitel, Viettel), Vodafone Idea

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

Contact information

For the GSMA
Gearóid Cashman
+44 79 7679 0169
GCashman@webershandwick.com

GSMA Press Office
pressoffice@gsma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting9.12.2019 20:00:00 EETPress release

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today presented data characterizing KB-3061, the lead molecule in the Company’s Kv7 ion channel platform, at the American Epilepsy Society’s (AES) 2019 Annual Meeting in Baltimore, Maryland. Knopp is advancing the development of KB-3061 as a potential precision medicine treatment for the rare, neonatal disease KCNQ2 epileptic encephalopathy (KCNQ2-EE), a genetically defined disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay. The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development. Data presented at AES by Knopp scientists and its academic collaborators support the continued development of KB-3061 as a potential treatment for children with KCNQ2-EE. K

Murray Energy Corporation Posts Information to its Website Related to Murray Metallurgical9.12.2019 18:46:00 EETPress release

Beginning on December 2, 2019, Murray Energy Corporation (the “Company”) engaged in confidential discussions under separate confidentiality agreements with certain members of an ad hoc group of superpriority lenders related Murray Metallurgical Coal Holdings, LLC and its subsidiaries (collectively, “Murray Metallurgical”). The confidentiality agreements require the Company to publicly disclose all material non-public information provided to such lenders on or prior to 8:30am (New York time) on December 9, 2019. The Company has posted certain previously undisclosed material to its website to satisfy its disclosure obligations under the confidentiality agreements. Such information can be viewed at the Investors portion of the Company’s website, located at murrayenergycorp.com/investors. Further inquiries should be directed to media@coalsource.com. Safe Harbor Statement The materials referenced in this release and posted to our website include forward-looking statements. A variety of fact

Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 20199.12.2019 18:00:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing personalized treatment. However, in von Willebrand disease, real-world evidence highlights the ongoing unmet clinical need for personalization, as it may enable improved treatment outcomes. Insights presented at ASH include: ADYNOVATE ® [Antihemophilic Factor (Recombinant), PEGylated]: In the poster “Real-World Age-Stratified FVIII Consumption and Bleed Outcom

Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting9.12.2019 18:00:00 EETPress release

Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab vedotin). These analyses were presented at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Fla. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas (PTCL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005169/en/ The ECHELON-1 analysis highlighted a four-year update of the phase 3 clinical trial in a poster presentation. ECHELON-1 is evaluating ADCETRIS in combination with AVD (Adriamycin [doxorubicin], vinblastine and dacarbazine) compared to ABVD (Adriamycin [doxorubicin], bleomycin, vinblasti

Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding9.12.2019 17:39:00 EETPress release

Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers", pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder and overdose. The grant was made to Indivior by the NIH in fiscal year 2019, to apply scientific solutions to reverse the national opioid crisis. In March 2018, Indivior entered into a license agreement with C4X Discovery Holdings PLC (C4X) whereby Indivior obtained exclusive global rights to develop and commercialize INDV-2000 (C4X_3256). The first-in-human, single-ascending-dose study will be conducted in two parts — Part I: double-blind, placebo-controlled, randomized, single-ascending-dose study in fasted condition. Part II:

Elliott Statement on Alexion9.12.2019 17:22:00 EETPress release

Funds advised by Elliott Advisors (UK) Limited (together “Elliott” or “we”) acknowledge the statement issued by Alexion Pharmaceuticals, Inc. (“Alexion” or “the Company”) on Friday. Elliott confirms that it has had a multiyear, constructive and private engagement with Alexion that has led to value-creative changes at the Company. Despite two years of strong execution that bolstered the Company’s strategic value, we believe Alexion remains significantly undervalued by the market. Elliott is encouraged by the Board’s public commitment to evaluate any inbound interest and its overall commitment to shareholder value creation. Elliott remains of the view that Alexion would be a highly valuable strategic and financial asset for a number of larger pharmaceutical companies. We also continue to believe that a proactive approach would maximise the chance of an optimal outcome. We look forward to continuing our dialogue with the Company in an effort to close the gap between its current share pric

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom